NICE publishes final draft guidance on icosapent ethyl
The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides, and who remain at a high residual risk of cardiovascular events.
The final draft guidance can be found on the website of NICE. The final guidance on icosapent ethyl is expected to be published in July 2022.
Share this page with your colleagues and friends: